WEST PHARMACEUTICAL SERVICES, INC. (WST) FY2026 Q2 P&L / Income Statement

WEST PHARMACEUTICAL SERVICES, INC. (WST) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

872,300,000 US dollars

Cost of goods and services sold

543,100,000 US dollars

Gross profit

329,200,000 US dollars

Operating costs, including other operating expenses (calculated)

150,100,000 US dollars

Operating profit

179,100,000 US dollars

Other income (expense), net (calculated)

1,000,000 US dollars

Income before income taxes and equity in net income of affiliated companies

180,100,000 US dollars

Income tax expense

32,200,000 US dollars

Net income

154,000,000 US dollars

Proprietary Products

722,600,000 US dollars

West Vantage

149,700,000 US dollars

Research and development

19,700,000 US dollars

Selling, general and administrative expenses

117,600,000 US dollars

Other expense (income) (Note 14)

12,800,000 US dollars

Equity in net income of affiliated companies

6,100,000 US dollars. Reported below-tax contribution to net income.

Proprietary Products costs (calculated)

510,700,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

West Vantage costs (calculated)

136,800,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Reconciling items (calculated)

45,700,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.